Free Trial
→ What Elon Musk's Cybercab Reveal Could Mean for Investors (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$69.13
-0.2%		$77.67
$53.54
▼
$151.02
$3.38B0.11.89 million shs700,079 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
-0.25%+5.95%-13.07%-19.97%-6.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$69.13
-0.2%		$77.67
$53.54
▼
$151.02
$3.38B0.11.89 million shs700,079 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
-0.25%+5.95%-13.07%-19.97%-6.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
2.69
Moderate Buy$152.57120.70% Upside

Current Analyst Ratings Breakdown

Latest CELC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/28/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeNeutral
10/22/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$140.00
10/21/2026
Celcuity, Inc. stock logo
CELC
Celcuity
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$145.00
10/19/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/13/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
9/30/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$140.00 ➝ $134.00
9/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$157.00
9/1/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$165.00 ➝ $175.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/5/2026 (Estimated)

Latest CELC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.50N/AN/AN/A$1.60 millionN/A
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
15548.93 million42.41 millionOptionable

Recent News About These Companies

Celcuity, Inc. $CELC Stock Sold by Simplicity Wealth LLC
October 31 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-celcuity-inc-celc-stock-sold-by-simplicity-wealth-llc-2026-10-31/
Celcuity (CELC) Expected to Post Earnings on Thursday
October 31 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31169237
Celcuity (CELC) Expected to Release Quarterly Earnings on Thursday
October 31 at 2:25 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-celcuity-celc-expected-to-release-quarterly-earnings-on-thursday-2026-10-31/
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
October 30 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4960075-celcuity-stronger-clinical-evidence-much-lower-valuation
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
October 29 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391271/0/en/celcuity-schedules-release-of-third-quarter-2026-financial-results-and-webcast-conference-call.html
Celcuity, Inc. (NASDAQ:CELC) Stock Has Consensus Target Price of $152.57 According to Brokerages
October 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-celcuity-inc-nasdaq-celc-stock-has-consensus-target-price-of-15257-according-to-brokerages-2026-10-27/
Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative
October 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/breast-prostate-cancer-data-change-201051418.html
Celcuity (CELC) Shares Dip Despite Strong VIKTORIA-1 Trial Results in Advanced Breast Cancer
October 24, 2026  |  moneycheck.comM
Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes
October 24, 2026  |  blockonomi.comhttps://blockonomi.com/celcuity-inc-celc-stock-promising-phase-3-breast-cancer-data-fuels-growth-hopes/
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-study-in-patients-with-hr-her2--advanced-breast-cancer-at-the-esmo-congress-2026-1036661996
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/24/3387663/0/en/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-study-in-patients-with-hr-her2-advanced-breast-cancer-at-the-esmo-congress-2026.html
Celcuity (NASDAQ:CELC) Stock Picked Up by Analysts at Cantor Fitzgerald
October 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151680
Celcuity Inc. Presents Updated Data From Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide In Men With Metastatic Castration-Resistant Prostate Cancer
October 23, 2026  |  marketscreener.comM
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress ...
October 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/celcuity-presents-updated-data-from-a-phase-1b-2-study-evaluating-gedatolisib-plus-darolutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-at-the-esmo-congress-2026-1036659592
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
October 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/23/3387293/0/en/celcuity-presents-updated-data-from-a-phase-1b-2-study-evaluating-gedatolisib-plus-darolutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-at-the-esmo-congress-202.html
Cantor Fitzgerald Initiates Celcuity at Overweight With $140 Price Target
October 22, 2026  |  marketscreener.comM
Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data
October 22, 2026  |  ibtimes.com.auI
Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
October 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cantor-sees-credible-path-multi-151423973.html
Cantor Fitzgerald initiates coverage of Celcuity with overweight rating
October 22, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/cantor-fitzgerald-initiates-coverage-of-celcuity-with-overweight-rating/ar-AA2fRqGG
Cantor Fitzgerald Initiates Coverage on Celcuity (NASDAQ:CELC)
October 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-cantor-fitzgerald-initiates-coverage-on-celcuity-nasdaq-celc-2026-10-22/
Celcuity (NASDAQ:CELC) Stock Price Up 8.5% - Here's What Happened
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-celcuity-nasdaq-celc-stock-price-up-85-heres-what-happened-2026-10-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$69.13 -0.17 (-0.25%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$69.18 +0.05 (+0.07%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas